Effects of Canagliflozin and Metformin on Insulin Resistance and Visceral Adipose Tissue in People With Newly-diagnosed Type 2 Diabetes
BMC Endocrine Disorders 2022;22:37 doi.org/10.1186/s12902-022-00949-0
In this study of patients with newly-diagnosed (<6 months) T2D, canagliflozin was associated with reduced insulin resistance and visceral adipose tissue compared with placebo.
Abdominal obesity is associated with insulin resistance and chronic inflammation. This study by Hao et al examined the effect of an SGLT2i, canagliflozin, on visceral adipose tissue and insulin resistance in T2D.